Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 6, 2013, Pages 757-766

  Janelsins, Michelle C ^a   Tejani, Mohamedtaki A ^a   Kamen, Charles ^a   Peoples, Anita R ^a   Mustian, Karen M ^a   Morrow, Gary R ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Anticipatory nausea and vomiting; Cancer treatments; Chemotherapy; Chemotherapy induced nausea and vomiting; Emesis; Nausea; Vomiting

Indexed keywords

ANTHRACYCLINE; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; APREPITANT; BENZODIAZEPINE; CANNABINOID; CARBAMAZEPINE; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOLASETRON MESILATE; DOXORUBICIN; FOSAPREPITANT; GABAPENTIN; GRANISETRON; METOCLOPRAMIDE; NETUPITANT; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; OLANZAPINE; PALONOSETRON; PLACEBO; PROMETHAZINE; SEROTONIN; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR;

BINDING AFFINITY; CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CORTICOSTEROID THERAPY; DRUG EFFICACY; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG SAFETY; HUMAN; MIGRAINE; MORNING DOSAGE; NEUROPATHIC PAIN; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTHERPETIC NEURALGIA; RECOMMENDED DRUG DOSE; REVIEW; SINGLE DRUG DOSE;

ANIMALS; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG DESIGN; HUMANS; NAUSEA; PRACTICE GUIDELINES AS TOPIC; QUALITY OF LIFE; VOMITING;

EID: 84875152856     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.776541     Document Type: Review

References (97)

1. Hickok JT, Roscoe JA, Morrow GR, et al. 5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: A URCC CCOP randomised controlled trial. Lancet Oncol 2005;6:765-72
2. Hofman M, Morrow GR, Roscoe JA, et al. Cancer patients' expectations of experiencing treatment-related side effects: A University of Rochester Cancer Center-Community Clinical Oncology Program study of 938 patients from community practices. Cancer 2004;101:851-7
3. Hickok JT, Morrow GW, Roscoe JA, et al. Prevalence and severity of acute and delayed NV association with 3 highly emetogenic chemotherapies. [abstract]. Support Care in Cancer 2001;9:289
4. Grunberg SM. Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: Dosing, efficacy, and tolerability analysis. Ann Oncol 2007;18:233-40
5. Aapro MS, Molassiotis A, Olver I. Anticipatory nausea and vomiting. Support Care Cancer 2005;13:117-21
6. Morrow GR, Roscoe JA, Kirshner JJ, et al. Anticipatory nausea and vomiting in the era of 5-HT3 antiemetics. Support Care Cancer 1998;6:244-7
7. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med 2008;358:2482-94
8. Figueroa-Moseley C, Morrow GR. Major advances and alternative approaches to antiemetic therapy. Oncology 2008;21. Available at: Www. cancernetwork.com/ nausea-and-vomiting/article/10165/59693
9. Schwartzberg LS. Chemotherapy-induced nausea and vomiting: Which antiemetic for which therapy? Oncology 2007;21:946-53
10. Grote T, Hajdenberg J, Cartmell A, et al. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: Palonosetron, dexamethasone, and aprepitant. J Support Oncol 2006;4:403-8
11. Wilhelm SM, Dehoorne-Smith ML, Kale-Pradhan PB. Prevention of postoperative nausea and vomiting. Ann Pharmacother 2007;41:68-78
12. Rhodes VA, McDaniel R. Nausea, vomiting, and retching: Complex problems in palliative care. CA Cancer J Clin 2001;51:232-48
13. Sanger GJ, Andrews PL. Treatment of nausea and vomiting: Gaps in our knowledge. Auton Neurosci 2006;129:3-16
14. Ingle RJ, Burish TG, Wallston KA. Conditionability of cancer chemotherapy patients. Oncol Nurs Forum 1984;11:97-102
15. Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American society of clinical oncology clinical practice guideline update. J Clin Oncol 2011;29:4189-98
16. Durand JP, Madelaine I, Scotte F. Guidelines for prophylaxis and treatment of chemotherapy-induced nausea and vomiting. Bull Cancer 2009;96:951-60
17. Roila F, Boschetti E, Tonato M, et al. Predictive factors of delayed emesis in cisplatintreated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. A randomized single-blind study. Am J Clin Oncol 1991;14:238-42
18. Kris MG, Gralla RJ, Clark RA, et al. Incidence, course, and severity of delayed nausea and vomiting following the administration of highdose cisplatin. J Clin Oncol 1985;3:1379-84
19. Roscoe JA, Morrow GR, Hickok JT, et al. Biobehavioral factors in chemotherapy-induced nausea and vomiting. J Natl Compr Canc Netw 2004;2:501-8
20. Herrstedt J, Rapoport B, Warr D, et al. Acute emesis: Moderately emetogenic chemotherapy. Support Care Cancer 2011;19(Suppl 1):S15-23
21. Bloechl-Daum B, Deuson RR, Marvos P, et al. Delayed nausea and vomiting continue to reduce patient's quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 2006;24:4472-8
22. Roscoe JA, Heckler CE, Morrow GR, et al. Prevention of delayed nausea: A university of Rochester cancer center community clinical oncology program study of patients receiving chemotherapy. J Clin Oncol 2012;30:3389-95
23. Roscoe JA, Morrow GR, Aapro MS, et al. Anticipatory nausea and vomiting. Support Care Cancer 2011;19(10):1533-8
24. Jacobsen PB, Redd WH. The development and management of chemotherapy-related anticipatory nausea and vomiting. Cancer Invest 1988;6:329-36
25. Moher D, Arthur AZ, Pater JL. Anticipatory nausea and/or vomiting. Cancer Treat Rev 1984;11:257-64
26. Morrow GR. Clinical characteristics associated with the development of anticipatory nausea and vomiting in cancer patients undergoing chemotherapy treatment. J Clin Oncol 1984;2:1170-6
27. Jordan K, Sippel C, Schmoll HJ. Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: Past, present, and future recommendations. Oncologist 2007;12:1143-50
28. Schwartzberg L. Chemotherapy-induced nausea and vomiting: State of the art in 2006. J Support Oncol 2006;4:3-8
29. Roscoe JA, Morrow GR, Aapro MS, et al. Anticipatory nausea and vomiting. Support Care Cancer
30. Nevidjon B, Chaudhary R. Controlling emesis: Evolving challenges, novel strategies. J Support Oncol 2010;8:1-10
31. Jacobsen PB, Redd WH. The development and management of chemotherapy-related anticipatory nausea and vomiting. Cancer Invest 1988;6:329-36
32. Moher D, Arthur AZ, Pater JL. Anticipatory nau sea and/or vomiting. Cancer Treat Rev 1984;11:257-64
33. Darmani NA, Ray AP. Evidence for a re-evaluation of the neurochemical and anatomical bases of chemotherapy-induced vomiting. Chem Rev 2009;109:3158-99
34. Hesketh PJ, VanBelle S, Aapro M, et al. Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer 2003;39:1074-80
35. Rudd JA, Andrews PL. Mechanisms of acute, delayed, and anticipatory emesis induced by anticancer therapies. Jones & Bartlett; Sudbury, MA: 2005
36. Feyer P, Jordan K. Update and new trends in antiemetic therapy: The continuing need for novel therapies. Ann Oncol 2011;22:30-8
37. Hornby PJ. Central neurocircuitry associated with emesis. Am J Med 2001;111:106S-12S
38. Rubenstein EB, Slusher BS, Rojas C, Navari RM. New approaches to chemotherapy-induced nausea and vomiting: From neuropharmacology to clinical investigations. Cancer J 2006;12:341-7
39. Hockenberry-Eaton M, Benner A. Patterns of nausea and vomiting in children: Nursing assessment and intervention. Oncol Nurs Forum 1990;17:575-84
40. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med 2008;358:2482-94
41. Rudd JA, Andrews PLR. editors. Chapter 2: Mechanisms of acute, delayed, and anticipatory emesis induced by anticancper therapies. Jones and Bartlett; Sudbury, MA; 2005
42. Leslie RA, Reynolds DJM. Chapter 6: Neurotransmitters and receptors in the emetic pathway. Chapman & Hall Medical; London; 1993
43. Blackshaw LA, Brookes SJ, Grundy D, Schemann M. Sensory transmission in the gastrointestinal tract. Neurogastroenterol Motil 2007;19:1-19
44. Burke CW, Mason JN, Surman SL, et al. Illumination of parainfluenza virus infection and transmission in living animals reveals a tissue-specific dichotomy. PLoS Pathog 2011;7
45. Lesurtel M, Soll C, Graf R, Clavien PA. Role of serotonin in the hepatogastrointestinal tract: An old molecule for new perspectives. Cell Mol Life Sci 2008;65:940-52
46. Gershon MD. Review article: Serotonin receptors and transporters-roles in normal and abnormal gastrointestinal motility. Aliment Pharmacol Ther 2004;20:3-14
47. Farber L, Haus U, Spath M, Drechsler S. Physiology and pathophysiology of the 5-HT3 receptor. Scand J Rheumatol Suppl 2004;119:2-8
48. Miner WD, Sanger GJ. Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br J Pharmacol 1986;88:497-9
49. Higgins GA, Kilpatrick GJ, Bunce KT, et al. 5-HT3 receptor antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferret. Br J Pharmacol 1989;97:247-55
50. del Giglio A, Soares HP, Caparroz C, Castro PC. Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting: Results of a meta-analysis of randomized controlled trials. Cancer 2000;89:2301-8
51. Palma C. Tachykinins and their receptors in human malignancies. Curr Drug Targets 2006;7:1043-52
52. Borison HL, McCarthy LE. Neuropharmacology of chemotherapy induced emesis. Drugs 1983;25:8-17
53. Diemunsch P, Grelot L. Potential of substance P antagonists as antiemetics. Drugs 2000;60:533-46
54. Girish C, Manikandan S. Aprepitant: A substance P antagonist for chemotherapy-induced nausea and vomiting. Indian J Cancer 2007;44:25-30
55. Herrstedt J. Antiemetics: An update and the MASCC guidelines applied in clinical practice. Nat Clin Pract Oncol 2008;5:32-42
56. Saito R, Takano Y, Kamiya HO. Roles of substance P and NK(1) receptor in the brainstem in the development of emesis. J Pharmacol Sci 2003;91:87-94
57. Hu WP, You XH, Guan BC, et al. Substance P potentiates 5-HT3 receptormediated current in rat trigeminal ganglion neurons. Neurosci Lett 2004;365:147-52
58. Minami M, Endo T, Yokota H, et al. Effects of CP-99,994, a tachykinin NK (1) receptor antagonist, on abdominal afferent vagal activity in ferrets: Evidence for involvement of NK(1) and 5-HT3 receptors. Eur J Pharmacol 2001;428:215-20
59. Darmani NA, Chebolu S, Amos B, Alkam T. Synergistic antiemetic interactions between serotonergic 5-HT (3) and tachykininergic NK(1)-receptor antagonists in the least shrew (Cryptotis parva). Pharmacol Biochem Behav 2011;99:573-9
60. Rojas C, Li Y, Zhang J, et al. The antiemetic 5-HT3 receptor antagonist palonosetron inhibits substance P-mediated responses in vitro and in vivo. J Pharmacol Exp Ther 2010;335:362-8
61. Higa GM, Auber ML, Altaha R, et al. Concordance between substance P levels and antiemetic guidelines. J Support Oncol 2009;7:138-42
62. Darmani NA, Crim JL, Janoyan JJ, et al. A re-evaluation of the neurotransmitter basis of chemotherapy-induced immediate and delayed vomiting: Evidence from the least shrew. Brain Res 2009;1248:40-58
63. Navari RM. Pharmacological management of chemotherapy-induced nausea and vomiting: Focus on recent developments. Drugs 2009;69:515-33
64. Nausea and Vomiting (PDQ). 2012.Available from: Http://www.cancer. gov/cancertopics/pdq/supportivecare/nausea/Patient/page1/AllPages/Print
65. Matteson S, Roscoe J, Hickok J, Morrow GR. The role of behavioral conditioning in the development of nausea. Am J Obstet Gynecol 2002;186:S239-43
66. Stockhorst U, Enck P, Klosterhalfen S. Role of classical conditioning in learning gastrointestinal symptoms. World J Gastroenterol 2007;13:3430-7
67. Roscoe JA, Morrow GR, Aapro MS, et al. Anticipatory nausea and vomiting. Support Care Cancer 2011;19:1533-8
68. Figueroa-Moseley C, Jean-Pierre P, Roscoe JA, et al. Behavioral interventions in treating anticipatory nausea and vomiting. J Natl Compr Canc Netw 2007;5:44-50
69. Morrow GR RJ, Hickok JT. Nausea and Vomiting. Oxford University Press; New York, NY; 1998
70. (APA) APA. Diagnostic and statistical manual of mental disorders. 4th edition. Text rev; 2000
71. Roscoe JA, Morrow GR, Aapro MS, et al. Anticipatory nausea and vomiting. Support Care Cancer 2011;19:1533-8
72. Colagiuri B, Roscoe JA, Morrow GR, et al. How do patient expectancies, quality of life, and postchemotherapy nausea interrelate? Cancer 2008;113:654-61
73. Hickok JT, Roscoe JA, Morrow GR. The role of patients' expectations in the development of anticipatory nausea related to chemotherapy for cancer. J Pain Symptom Manage 2001;22:843-50
74. Navari RM. Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer. Future Oncol 2010;6:1073-84
75. Aapro M, Grunberg S, Manikhas G, et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006;17:1441
76. Saito M, Aogi K, Sekine I, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: A double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 2009;10:115-24
77. Yu Z, Liu W, Wang L, et al. The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: A phase II, multicenter, randomized, double-blind, parallel, comparative clinical trial. Support Care Cancer 2009;17:99-102
78. Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003;21:4112
79. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003;97:3090-8
80. Herrstedt J, Muss HB, Warr DG, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer 2005;104:1548-55
81. Herrington JD, Jaskiewicz AD, Song J. Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Cancer 2008;112:2080-7
82. EMEND (fosaprepitant dimeglumine) for injection. Merck & Co., Inc. 2010.Available from: Http://www. accessdata.fda.gov/drugsatfda-docs/label/2010/ 022023s002s003s005lbl.pdf
83. Langford P, Chrisp P. Fosaprepitant and aprepitant: An update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomiting. Core Evid 2010;5:77
84. Strohscheer I, Borasio GD. Carbamazepine-responsive paroxysmal nausea and vomiting in a patient with meningeal carcinomatosis. Palliat Med 2006;20:549-50
85. Guttuso T Jr, Roscoe J, Griggs J. Effect of gabapentin on nausea induced by chemotherapy in patients with breast cancer. Lancet 2003;361:1703-5
86. Cruz FM, de Iracema Gomes Cubero D, Taranto P, et al. Gabapentin for the prevention of chemotherapy- induced nausea and vomiting: A pilot study. Support Care Cancer 2012;20:601-6
87. Navari RM, Einhorn LH, Loehrer PJ Sr, et al. A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: A Hoosier oncology group study. Support Care Cancer 2007;15:1285-91
88. Navari RM, Einhorn LH, Passik SD, et al. A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A Hoosier Oncology Group study. Support Care Cancer 2005;13:529-34
89. Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A randomized phase III trial. J Support Oncol 2011;9:188-95
90. NCCN Clinical Practice Guidelines in Oncology: Antiemetics. 2012.Available from: Http://www.nccn. org/professionals/physician-gls/pdf/ antiemesis.pdf [Accessed 5 November 2012]
91. Basch E, Hesketh PJ, Kris MG, et al. Antiemetics: American society of clinical oncology clinical practice guideline update. J Oncol Pract Am Soc Clin Oncol 2011;7:395-8
92. Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2011;29:4189-98
93. MASCC/ESMO Antiemetic Guideline 2011. 2011. Available from: Http://www.mascc.org/index.php? option=com-content&view=article& id=261 [Accessed 5 November 5 2012]
94. Mustian KM, Devine KR, Ryan JL, et al. Treatment of nausea and vomiting during chemotherapy. US Oncol Hematol 2011;7:91-7
95. Mustian KM, Darling T, Janelsins MJ, et al. Chemotherapy-induced nausea and vomiting. US Oncol 2008;4:19-23
96. O'Kane A. Evaluate the effects Of implementing the Multinational Association Of Supportive Care In Cancer (MASCC) antiemetic guideline on the incidence of Chemotherapy-Induced Nausea And Vomiting (CINV) following platinum chemotherapy. Support Care Canr 2009;17:875
97. Roila F, Warr D, Aapro M, et al. Delayed emesis: Moderately emetogenic chemotherapy (single-day chemotherapy regimens only). Support Care Canrcer 2011;19(Suppl 1):S57-62